Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06913023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06913023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Lead sponsor
University Health Network, Toronto
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 5, 2026
Completion date
December 30, 2029
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant recipient